晚期肺腺癌靶向治疗72例临床研究

《晚期肺腺癌靶向治疗72例临床研究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、晚期肺腺癌靶向治疗72例临床研究【摘要】目的：分析并探讨晚期肺腺癌靶向治疗的临床效果，为今后的肿瘤治疗方向提供一定的理论依据。方法：选取2010年5月-2014年5月本院呼吸内科收治的72例晚期肺腺癌患者作为研究对象。其中一线治疗22例，二线治疗50例。口服250mg的吉非替尼，1次/d，服药前后lh内不能服用其他药物，连续服用直到肿瘤进展或发生不可耐受的副作用。针对骨转移患者提供哇来膦酸、合并脑转移患者提供r刀放射治疗。结果：一线治疗患者中CR6例，PR9例，SD7例，中位缓解时间（7.6±0.5）个月，中位肿瘤

2、进展时间（8.5±0.6）个月，随访4〜24个月，中位随访14个月，死亡4例；二线治疗的忠者中PR8例，SD26例，PD16例，中位缓解时间（6.5±0.4）个月，中位肿瘤进展时间（7.2±0.5）个月，随访4〜30个月，中位随访12个月，8例患者死亡。一线治疗总有效率高于二线治疗，比较差异有统计学意义（P【关键词】晚期肺腺癌；靶向治疗；吉非替尼【Abstract】Objective：Toanalyzeandstudytheclinicaleffectoftargetedtherapyinthetreatmento

3、fadvancedlungadenocarcinomaandtoprovidecertaintheoreticalbasisforthefuturedirectionofcancertherapy.Method：72casesoflungadenocarcinomapatientsintherespiratorymedicineofourhospitalfromMay2010toMay2014wereselectedastheresearchobjects.22casesweregivenfirst-linetre

4、atment，50casesweregivensecond-linetreatment.PatientsweregivenGefitiniborallyatadoseof250mgperdayandtheycouldn'ttakeotherdrugswithin1hourbeforeandafterdruguse.Thistreatmentwascontinueduntilthetumorprogressionortheoccurrenceofintolerablesideeffects.Patientswithb

5、onemetastasesweregivenZoledronicacidandpatientswithbrainmetastasisweregivenrkniferadiotherapy.Result：Inthepatientswithfirst-linetreatment，6caseswerecompleteremission,9caseswerepartialresponseand7caseswerestability.Themedianalleviatetimewas(7.6土0.5)months，theme

6、diantumorprogressiontimewas(8.5土0.6)monthsandthemedianfollow-upwas14months(4-24months).4patientswithfirst-linetreatmentdied.Amongthepatientswithsecond-linetreatment,8caseswerepartialresponse，26caseswerestabilityand16caseswerepartialresponse，themedianrelieftime

7、was(6.5±0.4)months，themediantumorprogressiontimewas(7.2±0.5)monthsandthemedianfollow-upwas12months(4-30months).8patientswithsecond-linetreatmentdied.Thetotaleffectiverateofthefirst-linetreatmentwashigherthanthatofthesecond-linetreatment，thedifferencewasstatist

8、icallysignificant(P【Keywords】Advancedlungadenocarcinoma；Targetedtherapy；Gefitinib肺腺癌是肺癌的一种，致死率很高，根据肿瘤研究网站的相关数据表明：全球毎年因肺腺癌死亡的人数高达140万，且数据呈现出逐年增长的趋势［1］。靶向药物吉非替尼凭借副作用小、疗效显著等方式备受关注，本研究